Killer cell lectin-like receptor subfamily K member 1 – T-cell receptor signaling complex (KLRK1-TCR complex)

The KLRK1 – T-cell receptor (TCR) signaling complex represents the functional integration of the NKG2D (KLRK1) activating receptor with the primary T-cell receptor signaling machinery [1, 2]. KLRK1 is a C-type lectin-like receptor expressed on natural killer (NK) cells, CD8+ T cells, and γδ T cells, where it typically associates with the adapter protein DAP10 to initiate downstream signaling [1]. In T cells, KLRK1 acts as a potent costimulatory signal that can lower the activation threshold of the TCR or, in some inflammatory conditions, trigger TCR-independent effector functions [2, 3]. This complex is a critical target in oncology, where NKG2D-based chimeric antigen receptor (CAR) T cells and bispecific engagers are designed to harness its potent cytotoxic potential against ligand-expressing tumor cells [5]. Conversely, in autoimmune and inflammatory diseases like Crohn's disease and rheumatoid arthritis, the KLRK1-TCR axis is often overactive, leading to tissue damage, and is targeted by antagonistic antibodies to dampen the immune response [3, 4]. Therapeutic challenges include managing on-target, off-tumor toxicities, as NKG2D ligands (such as MICA/B) can be upregulated on healthy tissues under stress [3]. The synergy between KLRK1 and TCR signaling is also a focus for developing next-generation immunotherapies that aim to enhance T-cell persistence and polyfunctionality within the immunosuppressive tumor microenvironment [2, 5].

Other names

NKG2D-TCR complexCD314-TCR complexKLRK1-CD3 complexNKG2D-CD3 signaling unit

Antagonism of the KLRK1 (NKG2D) component to inhibit T-cell mediated inflammation in autoimmune diseases [4]; Agonism or chimeric expression (CAR) to enhance T-cell and NK-cell cytotoxicity against ligand-expressing tumor cells [5]; Bispecific engagement to bridge T-cells to tumor cells via the TCR and NKG2D pathways [3].